Steven A. Shallcross

Steven A. Shallcross (chief executive) discloses dealings in 4 companies, chiefly Vanda Pharmaceuticals Inc., Theriva Biologics, Inc. and Elys Game Technology, Corp. Over a trading history stretching from 11 December 2006 to 7 June 2023, the count stands at 53 filings.

On the open market, the record shows 11 purchases worth €211k and 24 sales worth €725k. On balance, insiders were net sellers of €514k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 2 share grants and 16 option exercises. 2023 to date brings 7 purchases and no sales.

In size, the median ticket on the buying side is €19k. Across 9 purchases, this insider has always bought alone, with no colleague buying within 30 days.

On 8 June 2023 came the latest disclosure, an open-market purchase for €9,062 in Theriva Biologics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.